参考文献: [1]NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), Breast Cancer, Version 6.2024, November 11, 2024. [2]Turner NC, Im SA, Saura C, et al. Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast...
[1].Slamon D, Stroyakovskiy D, Yardley D, et al. Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2− early breast cancer: primary results from the Phase III NATALEE trial. Presented at the American Society of Clinical Oncology Annual Meeting; June 2, 2023;...
[1].Slamon D, Stroyakovskiy D, Yardley D, et al. Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2− early breast cancer: primary results from the Phase III NATALEE trial. Presented at the America...
参考文献: [1]NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), Breast Cancer, Version 6.2024, November 11, 2024. [2]Turner NC, Im SA, Saura C, et al. Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer. N Engl J Med. 2024 Oct 31;391(17):1584-1596. ...
近日,NCCN正式发布了2024.V4版乳腺癌诊疗指南1。新版指南相较于2023.V5版2进行了大量修订,涉及导管原位癌、HER2-乳腺癌(包括HR+/HER2-、三阴性乳腺癌等)、HER2+、NTRK基因融合等不同亚型重磅内容。 医脉通小编将更新内容整理如下,并特邀复旦大学附属华东医院葛睿教授对重磅更新要点进行解读,让我们追随大咖的视角,...
b.出自“Hewitt M, Greenfield S, Stovall E. From Cancer Patient to Cancer Survivor: Lost in Transition. Committee on Cancer Survivorship: Improving Care and Quality of Life, Institute of Medicine and National Research Council 2006”。可登陆以下网站获取信息:...
11月11日,美国国家综合癌症网络(NCCN)更新了乳腺癌2024.V6版本指南[1],与2024.V5版本相比仅有细微改动。本次更新的主要内容为: 新增inavolisib+哌柏西利+氟维司群一线治疗晚期PIK3CA激活突变、激素受体(HR)阳性/人表皮生长因子受体2(HER2)阴性乳腺癌的适应证。 医学界小编特整理本次乳腺癌指南更新的精华内容,以...
1. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), Breast Cancer, Version 4.2024, July 3, 2024 2. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), Breast Cancer, Version 5.2023, December...
et al. Ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) as adjuvant treatment in patients with HR+/HER2- early breast cancer: final invasive disease-free survival (iDFS) analysis from the NATALEE trial. Presented at San Antonio Breast Cancer Symposium (SABCS); December 8, 2023; San...